Belimumab (Benlysta): A breakthrough therapy for systemic lupus erythematosus

P and T

Volumn 37, Issue 4, 2012, Pages 212-226

  Lamore, Raymond ^a   Parmar, Sapna ^b   Patel, Khilna ^c   Hilas, Olga ^c  

^a JOHNS HOPKINS HOSPITAL   (United States)

^b STONY BROOK UNIVERSITY MEDICAL CENTER   (United States)

^c ST JOHN'S UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ANTIMALARIAL AGENT; ANTINUCLEAR ANTIBODY; ASPARTATE AMINOTRANSFERASE; AZATHIOPRINE; B CELL ACTIVATING FACTOR; BELIMUMAB; CD19 ANTIGEN; CD20 ANTIGEN; CHLORAMBUCIL; COMPLEMENT COMPONENT C3; COMPLEMENT COMPONENT C4; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DOUBLE STRANDED DNA ANTIBODY; HORMONE; HYDROXYCHLOROQUINE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IMMUNOGLOBULIN G; IMMUNOMODULATING AGENT; IMMUNOSUPPRESSIVE AGENT; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; PHOSPHOLIPID ANTIBODY; PLACEBO; SM ANTIBODY;

AFRICAN AMERICAN; AGE; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANAPHYLAXIS; ANXIETY DISORDER; AREA UNDER THE CURVE; ARTHRITIS; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; B LYMPHOCYTE; BLOOD CELL COUNT; BRONCHITIS; CELL DIFFERENTIATION; CELL PROLIFERATION; CREATININE CLEARANCE; DEPRESSION; DIARRHEA; DISCOID LUPUS ERYTHEMATOSUS; DISEASE ACTIVITY; DRUG COST; DRUG EFFICACY; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; DRUG SAFETY; DRUG WITHDRAWAL; DYSPNEA; EARLY DIAGNOSIS; ECHOGRAPHY; ENVIRONMENT; ERYTHEMA; EXERCISE; EYELID EDEMA; FEVER; GENETICS; HEADACHE; HISPANIC; HUMAN; IMMUNIZATION; INFUSION RELATED REACTION; INSOMNIA; LIFE EXPECTANCY; LIFESTYLE MODIFICATION; LIMB PAIN; LUPUS ERYTHEMATOSUS NEPHRITIS; LUPUS LIKE SYNDROME; MAXIMUM PLASMA CONCENTRATION; MIGRAINE; NAUSEA; NEWBORN LUPUS ERYTHEMATOSUS; NUTRITION; PHARYNGITIS; PHASE 3 CLINICAL TRIAL (TOPIC); PLEURISY; PRURITUS; QUALITY OF LIFE; RACE; RASH; RECOMMENDED DRUG DOSE; RHINOPHARYNGITIS; RISK FACTOR; SENSITIVITY AND SPECIFICITY; SMOKING CESSATION; SYSTEMIC LUPUS ERYTHEMATOSUS; THORAX RADIOGRAPHY; TREATMENT DURATION; UPPER RESPIRATORY TRACT INFECTION;

EID: 84860848062     PISSN: 10521372     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. Helmick CG, Felson DT, Lawrence RC, et al. Estimates of the prevalence of arthritis and other rheumatic conditions in the United States: Part I. Arthritis Rheum 2008;58:15-25.
2. National Institute of Arthritis and Musculoskeletal and Skin Diseases. Handout on Health: Systemic Lupus Erythematosus. NIH No. 09-4178, August 2011 (online). Available at: www.niams.nih.gov/ Health_Info/Lupus/default.asp. Accessed January 30, 2011.
3. Bartels C, Diamond H, Muller D, et al. Systemic lupus erythematosus. Updated January 18, 2012. Available at: www. emedicine.medscape.com/article/ 332244-overview. Accessed January 30, 2011.
4. Griffiths B, Mosca M, Gordon C. Assessment of patients with systemic lupus erythematosus and the use of lupus disease activity indices. Best Pract Res Clin Rheumatol 2005;19:658-708.
5. Borigini M. Systemic lupus erythematosus. Last reviewed February 14, 2011. Available at: www.ncbi.nlm.nih.gov/pubmedhealth/ PMH0001471. Accessed March 20, 2011.
6. Isenberg DA, Gordon C. From BILAG to BLIPS: Disease activity assessment in lupus past, present, and future. Lupus 2000;9:651-654.
7. Petri M, Buyon J, Kim M. Classification and definition of major flares in SLE clinical trials. Lupus 1999;8:685-691.
8. Lam GKW, Petri M. Assessment of systemic lupus erythematosus. Clin Exp Rheumatol 2005;23(Suppl 39):S120-S132.
9. Rahman A, Isenberg DA. Systemic lupus erythematosus. N Engl J Med 2008;358: 929-939.
10. Delafuente J, Cappuzzo K. Systemic lupus erythematosus and other collagenvascular disease. In: DiPiro JT, Talbert RL, Yee GC, et al., eds. Pharmacotherapy: A Pathophysiologic Approach, 7th ed. New York: McGraw-Hill; 2005:761.
11. Benlysta (belimumab). Rockville, Md.: Human Genome Sciences, 2011. Available at: www.hgsi.com/benlysta-belimumab-3.html. Accessed March 9, 2011.
12. Benlysta (belimumab) for Injection, prescribing information. Rockville, Md.: Human Genome Sciences, Inc.; revised March 2011. Available at: www.hgsi. com/images/Benlysta/pdf/benlysta_pi. pdf. Accessed September 23, 2011.
13. Furie R, Stohl W, Ginzler EM, et al. Biologic activity and safety of belimumab, a neutralizing anti-B-lymphocyte stimulator (BLyS) monoclonal antibody: A phase I trial in patients with systemic lupus erythematosus. Arthritis Res Ther 2008;10: R109.
14. Navarra SV, Guzmán RM, Gallacher AE, et al. Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: A randomised, placebocontrolled, phase 3 trial. Lancet 2011;377: 721-731.
15. Van Vollenhoven R, Zamani O, Wallace DJ, et al. Belimumab, a BLyS-specific inhibitor, reduces disease activity and severe flares in seropositive SLE patients: BLISS-76 study (Abstract). Ann Rheum Dis 2010;69(Suppl 3):74.
16. Furie RA, Zamani O, Wallace DJ, et al. Belimumab, a BLyS-specific inhibitor, reduced disease activity and severe flares in seropositive SLE patients: BLISS-76 study results through wk 76 (Abstract). Arthritis Rheum 2010;62(Suppl 10):606.
17. Petri M, Levy RA, Merrill JT, et al. Belimumab, a BLyS-specific inhibitor, reduced disease activity, flares, and prednisone use in patients with seropositive SLE: Combined efficacy results from the phase 3 BLISS-52 and-76 studies (Abstract). Arthritis Rheum 2010;62(Suppl 10):190.
18. Benlysta (belimumab) lyophilized powder for intravenous infusion. GlaxoSmith Kline/Human Genome Sciences: Managed Care Dossier; March 2011.
19. Nault K. The changing face of SLE therapy and why Benlysta isn't for everyone. Lupus Magazine archive, April 2, 2011. Available at: http://thelupusmagazine. blogspot.com/2011/04/why-benlystaisnt-for-everyone-changing.html. Accessed January 30, 2012.
20. Market Snapshot: After Benlysta breakthrough, how high the sky in lupus? Bio-Pharma Today, October 13, 2009. Available at: www.biopharmatoday.com/ 2009/10/market-snapshot-after-benlystabreakthrough-how-high-the-sky-in-lupus. html. Accessed April 19, 2011.
21. Benlysta, Human Genome Sciences/ GlaxoSmithKline. Available at: www. benlystahcp.com. Accessed January 31, 2012.
22. Pollack A. FDA approves drug for lupus, an innovation after 50 years. The New York Times, March 9, 2011. Available at: www.nytimes.com/2011/03/10/health/ 10drug.html. Accessed April 19, 2011.